Clinical Trials Browser

Penile Squamous Cell Carcinoma (PSCC)

Muscle-invasive Bladder Cancer

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Transitional Cell

Neoplasm Metastasis

Salivary Gland Neoplasms

Carcinoma, Hepatocellular, Colorectal Neoplasms

Carcinoma, Adenoid Cystic

Carcinoma, Transitional Cell

Metastatic Urothelial Cancer

Muscle Invasive Bladder Urothelial Carcinoma

Carcinoma, Transitional Cell

Carcinoma, Transitional Cell

Metastatic Castration-resistant Prostate Cancer

Renal Pelvis and Ureter Urothelial Carcinoma

Carcinoma, Transitional Cell, Neoplasm Metastasis

Adenocarcinoma of the Bladder

Endometrial Neoplasms

Urinary Bladder Neoplasms

Penile Neoplasms

Urinary Bladder Neoplasms, Ureteral Neoplasms

Metastatic Urothelial Cancer

Carcinoma, Renal Cell

Urinary Bladder Neoplasms

Carcinoma, Transitional Cell

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Ureteral Neoplasms

Pancreatic Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

Carcinoma, Transitional Cell

Clinical Trials

DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

TROPHY U-01

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

IMPROEV

A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract

ENCORE

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

Circulating Tumor DNA Response In Urothelial Cancer

Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)

EV-4-EC

Renal Retention in High Grade Upper Tract Urothelial Cancer

Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis

RECIPE-B1

A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy

PlugIN

REPRINT

Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)

NEPTUNE

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)

StrataPATH

EV-201

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma